Coenzyme Q and weight loss -
There were also significant differences in fasting insulin 2. As for lipid profile, there were no significant differences in all markers between the two groups at week 0 and 12 [ 17 ].
At week 24, TG 0. Furthermore, in order to investigate the adipokine changes by CoQ10 intervention, we detected three serum adipokines, which were adiponectin, leptin and resistin at baseline, week 12 and As displayed in Table 2 , concentration of three adipokines were not significant different between two intervention groups at baseline.
Change of leptin levels did not differ significantly between two groups at week 12 or week Moreover, we performed a correlation analysis to establish the relationship between adipokine profiles change and glucolipid related markers that had been improved in CoQ10 intervention study.
Correlations of adipokines with markers of glucose and lipid metabolism are displayed in Fig. Correlation of adipokines with glucolipid profile.
Correlation analysis between the week change in serum adiponectin and HOMA-IR index a , LDL-c b and TG c in placebo and CoQ10 group, respectively. Correlation analysis between the week change in serum resistin and HOMA-IR index d and TG e in placebo and CoQ10 group, respectively. The data were evaluated by Pearson correlation coefficient r.
HOMA-IR, homeostasis model assessment of insulin resistance; LDL-c, low-density lipoprotein cholesterol; TG, triglyceride. To further investigate the possible mechanism that adipokines mediated the relationship between CoQ10 and glucolipid metabolism, we performed mediation analysis in significantly correlated adipokines and glucolipid related markers in CoQ10 intervention group.
Change of adiponectin or resistin between 24 weeks was set as mediator variate M. As the effect of CoQ10 on HOMA-IR mediated by both adipokines, we further conducted a multiple mediation analysis which included both adiponectin and resistin as mediator variates.
In CoQ10 group, change in adiponectin and resistin was correlated with the improvement of glucolipid profile. Moreover, mediating analysis indicated that CoQ10 improve glucolipid metabolism by affecting adiponectin.
As a lipophilic antioxidant, CoQ10 regulated lipid and glucose profile in a series of diseases, such as diabetes [ 22 ] and metabolic syndrome [ 23 ]. Consistently, our study also concluded that in Chinese dyslipidemia patients, long-term CoQ10 supplementation improved their insulin sensitivity and lipid profile.
Though less powerful and cost-effective than clinical medication in lipid lowering and hypoglycemic therapy, CoQ10 has benefits on multiple risk factors of cardiovascular disease, including lowering blood pressure [ 17 ], blood glucose, lipids and HOMA-IR with few side effect.
Therefore, CoQ10 is quite a good option for those who have moderate dyslipidemia with multiple metabolic disorders. Leptin is a reliable marker of percentage of fat mass [ 24 ]. Increased circulating leptin was observed in insulin resistance and T2DM [ 25 ] and correlated positively with lipids levels [ 26 ].
In previous studies, CoQ10 supplementation significantly reduced leptin levels in individuals with non-alcoholic fatty liver disease [ 27 ] and type 2 diabetes [ 28 ], which were inconsistent with our study.
The conflicting results may come from that the baseline serum level of leptin in the present study median, Accordingly, participants in our study were much thinner mean BMI was Our results also shown that CoQ10 did not cause significant weight loss [ 17 ].
Therefore, it was not surprising to observe a less remarkable improvement in leptin in subjects who per se had moderate increased of leptin and BMI.
However, we cannot totally rule out the possibility that CoQ10 can influence leptin secretion. Several published RCTs had reported conflicting effect of CoQ10 in adiponectin in non-alcoholic fatty liver disease [ 27 ], hypertension [ 29 ] and type 2 diabetes [ 28 ].
The increase of adiponectin was parallel with the ameliorative effects on lipid peroxidation and glucose control [ 30 ].
Results from our present study were consistent with these trials. However, studies conducted in type 2 diabetes [ 31 ] and healthy, nonsmoking, sedentary men [ 32 ] found that CoQ10 supplementation for 8 weeks showed no improvement in adiponectin. The limited intervention time less than 12 weeks and mild illness condition may account for the negative results of adiponectin responded to CoQ10 supplementation.
In this study, we not only found that CoQ10 increased adiponectin, but also found that CoQ10 ameliorated glucolipid profile by mediating adiponectin.
Adiponectin was thought as a protective adipokine. Extensive evidence have demonstrated anti-atherosclerotic, anti-diabetic, and anti-inflammatory activities that adiponectin possessed [ 33 ].
The gene expression of adiponectin is tightly controlled by a number of factors. PPAR-γ, which is expressed mainly in adipose tissue, is the major positive regulator of adiponectin gene expression. In contrast, inflammation factors such as tumor necrosis factor-alpha TNF-α inhibit adiponectin gene expression [ 34 ].
Interestingly, CoQ10 intervention can raise the expression of PPAR-γ in peripheral blood mononuclear cells of subjects with polycystic ovary syndrome [ 35 ]. CoQ10 can also partially attenuate the effect of TNF-α on PPAR-γ in HL-1 cardiomyocytes [ 36 ]. These results further suggested that adiponectin may be an important pathway and target of CoQ10 to improve lipid and glucose metabolic disorders.
However, more studies were needed to further confirm them. In human, resistin is synthesized predominantly by mononuclear cells inside and outside adipose tissues [ 37 , 38 ]. It can increase the production of the proinflammatory cytokines such as TNF-α and interleukin-6 IL-6 [ 39 , 40 ]. As we known, chronic inflammation was involved in the pathogenesis of obesity, type 2 diabetes and atherosclerosis.
Therefore, resistin has been suggested as an important modulator and predictor of metabolic diseases [ 41 , 42 ]. To our knowledge, this is the first study to investigate the effect of CoQ10 on resistin.
Supplementation of CoQ10 for 24 weeks reduced serum resistin. Though change in resistin concentration was positive correlated with the change in HOMA-IR and TG in CoQ10 group, mediating analysis showed that resistin did not involve in the regulation mechanism of CoQ10 on these two parameters when considering adiponectin, which indicated that adiponectin is a more important mediator in regulating glucose and lipid.
Another possible reason is that the reduction of resistin was accompanied by the improved of glucose and lipid.
As resistin has been suggested as a marker of the severity of myocardium ischemic injury [ 43 ], the change of resistin by CoQ10 in dyslipidemic patients indicated a further decreased risk for them to develop atherosclerosis.
There were several limitations in this study. Firstly, we did not adjust the diet CoQ10 content as a cofactor in comparison of the effect between two groups. The CoQ10 content in Chinese food have not yet been well examined. Moreover, according to 3-day h dietary record, the intake of energy, protein, total fat and total carbohydrate at baseline and during the week intervention of two group was comparable [ 17 ].
Adjusted for or week physical activity and energy intake did not change the beneficial effect of CoQ10 on metabolic variables compared to placebo [ 17 ].
This suggested that CoQ10 intake by diet did not significantly affect the results of the intervention. Secondly, serum CoQ10 had not been estimated before and after intervention. But we assessed compliance by counting the empty pill containers and inquiry adverse reaction every 4 weeks.
Thirdly, we did not deeply investigate the pathway behind CoQ10 and glucolipid metabolism in sophisticated experiment. But the mediation analysis revealed the important mediating role of adiponectin between CoQ10 and glucolipid metabolism.
It provided the direction for further research. In conclusion, we report that CoQ10 supplementation increase adiponectin and decrease resistin concentrations in dyslipidemic adults, which is correlated with the HOMA-IR and lipid profiles.
Data suggested that the improvement of CoQ10 on glucolipid metabolism in dyslipidemic adults was partly by modulating adiponectin. Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of , adults.
Int J Cardiol. Article PubMed Google Scholar. Lee YH, Lee SG, Lee MH, Kim JH, Lee BW, Kang ES, Lee HC, Cha BS. Serum cholesterol concentration and prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in the Korea National Health and Nutrition Examination Surveys — Beyond the Tip of the Iceberg.
J Am Heart Assoc. Article Google Scholar. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, Grundy SM, Johnson CL. Trends in serum lipids and lipoproteins of adults, — Article CAS PubMed Google Scholar. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, Itakura H, Ishikawa Y, Ouchi Y, Horibe H, Shirahashi N, Kita T.
Prevalence of metabolic syndrome in the general Japanese population in J Atheroscler Thromb. Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, Catapano AL. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies.
Nutr Metab Cardiovasc Dis. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
Article CAS Google Scholar. Unamuno X, Gomez-Ambrosi J, Rodriguez A, Becerril S, Fruhbeck G, Catalan V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V.
Obesity and dyslipidemia. Schindler M, Pendzialek M, Grybel KJ, Seeling T, Gurke J, Fischer B, Navarrete SA. Adiponectin stimulates lipid metabolism via AMPK in rabbit blastocysts.
Hum Reprod. Article CAS PubMed PubMed Central Google Scholar. Ayer A, Macdonald P, Stocker R. CoQ 1 0 function and role in heart failure and ischemic heart disease. Annu Rev Nutr. Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues.
Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q Proc Natl Acad Sci U S A. Shults CW, Haas RH, Passov D, Beal MF.
Ann Neurol. Kishi T, Kishi H, Watanabe T, Folkers K. Bioenergetics in clinical medicine. Studies on coenzyme Q and diabetes mellitus. J Med. CAS PubMed Google Scholar. Stojanovic M, Radenkovic M. A meta-analysis of randomized and placebo-controlled clinical trials suggests that coenzyme Q10 at low dose improves glucose and HbA1c levels.
Nutr Res. Suksomboon N, Poolsup N, Juanak N. Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. J Clin Pharm Ther. Zhang P, Yang C, Guo H, Wang J, Lin S, Li H, Yang Y, Ling W. Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals.
J Clin Lipidol. Anderson RL, Hamman RF, Savage PJ, Saad MF, Laws A, Kades WW, Sands RE, Cefalu W. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance FSIGT tests.
The Insulin Resistance Atherosclerosis Study. Am J Epidemiol. Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.
Diabetes Care. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SJ, Spertus JA, Costa F.
Mehrdadi P, Kolahdouz MR, Alipoor E, Eshraghian MR, Esteghamati A, Hosseinzadeh-Attar MJ. Exp Clin Endocrinol Diabetes. Raygan F, Rezavandi Z, Dadkhah TS, Farrokhian A, Asemi Z. The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome.
Eur J Nutr. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Et A. Serum immunoreactive-leptin concentrations in normal-weight and obese humans.
N Engl J Med. Bidulescu A, Dinh PJ, Sarwary S, Forsyth E, Luetke MC, King DB, Liu J, Davis SK, Correa A. Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study.
BMC Endocr Disord. Ostlund RJ, Yang JW, Klein S, Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates.
J Clin Endocrinol Metab. Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial.
J Am Coll Nutr. Gholami M, Zarei P, Sadeghi Sedeh B, Rafiei F, Khosrowbeygi A. Effects of coenzyme Q10 supplementation on serum values of adiponectin, leptin, 8-isoprostane and malondialdehyde in women with type 2 diabetes.
Gynecol Endocrinol. Bagheri NN, Mozaffari-Khosravi H, Najarzadeh A, Salehifar E. The effect of coenzyme Q10 supplementation on pro-inflammatory factors and adiponectin in mildly hypertensive patients: a randomized, double-blind, placebo-controlled trial.
Int J Vitam Nutr Res. Dludla PV, Orlando P, Silvestri S, Marcheggiani F, Cirilli I, Nyambuya TM, Mxinwa V, Mokgalaboni K, Nkambule BB, Johnson R, Mazibuko-Mbeje SE, Muller C, Louw J, Tiano L. Coenzyme Q10 supplementation improves adipokine levels and alleviates inflammation and lipid peroxidation in conditions of metabolic syndrome: a meta-analysis of randomized controlled trials.
Int J Mol Sci ; Moazen M, Mazloom Z, Ahmadi A, Dabbaghmanesh MH, Roosta S. Effect of coenzyme Q10 on glycaemic control, oxidative stress and adiponectin in type 2 diabetes. J Pak Med Assoc.
PubMed Google Scholar. Gokbel H, Gergerlioglu HS, Okudan N, Gul I, Buyukbas S, Belviranli M. Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men.
J Med Food. Maeda N, Funahashi T, Matsuzawa Y, Shimomura I. Adiponectin, a unique adipocyte-derived factor beyond hormones. Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol.
Rahmani E, Jamilian M, Samimi M, Zarezade MM, Aghadavod E, Akbari E, Tamtaji OR, Asemi Z. The effects of coenzyme Q10 supplementation on gene expression related to insulin, lipid and inflammation in patients with polycystic ovary syndrome.
Lee TI, Kao YH, Chen YC, Chen YJ. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA.
Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF.
Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes Lond. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes.
PLoS ONE. Article PubMed PubMed Central Google Scholar. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA.
Another reason for supplementing with coQ10 is because it is easily affected by the heat from cooking. Therefore, it is best to get it from raw foods, but the best sources are not recommended to be eaten raw.
CoQ10 has plenty of benefits. As already mentioned, it is a well-known antioxidant. Antioxidants are compounds that neutralize damaged particles known as free radicals to protect your cells from damage.
The results tend to be a bit mixed when it comes to weight loss and coQ Some studies show the coQ10 weight loss impact on animals, but no evidence proves the impact on human bodies. Because of its role in enhancing cellular energy, it is marketed for weight loss. Coenzyme Q10 is necessary for a part of the Krebs cycle, a series of chemical reactions that turns fat and glucose into ATP.
CoQ10 acts like the electron transport chain. When fat stored in cells breaks down into fatty acids that turn into acetyl CoA molecules, coQ10 binds with them and helps transport them throughout the Krebs cycle. CoQ10 also stimulates an enzyme that controls energy balance in cells, reducing fat accumulation that can lead to obesity and diabetes.
It may also reduce the risk of metabolic syndrome, which is also linked to obesity and diabetes. CoQ10 affects weight loss by optimizing the way cells use energy. This coenzyme accelerates BMR, basal metabolic rate, so your body burns more calories at rest.
CoQ10 contributes to lipolysis in a few ways:. Besides coQ10, supplementing with phentermine for weight loss is very popular. It is used to suppress appetite by increasing the levels of neurotransmitters in your brain.
There is no set rule, but a typical dosage is up to mg per day for adults. The dosage depends on age, health condition, gender, and purpose. Coenzyme Q10 comes in two forms: ubiquinone and ubiquinol. When ubiquinone is taken orally, once it reaches the lymphatic circulation, it gets converted into ubiquinol, which is the active form of the supplement.
When ubiquinol is taken, it has to be converted to ubiquinone first, and when it reaches the circulation, it gets converted back to ubiquinol. They both have the same effect, but their efficiency differs for different ages—another reason to consult a professional.
Our weight loss clinic is just a call away, and you can schedule your consultation now. Taking supplements without medical approval might cause side effects. Supplementing with coQ10 for weight loss seems safe; however, you have to be cautious. Get permission from your physician if you plan on supplementing with it.
To sum up, coQ10 has been shown to affect your body positively.
Although coenzyme Wight CoQ10 is best weighg for its losa Team-building fitness challenges heart health, few people know that CoQ10 also plays a Coenyme role in metabolic Team-building fitness challenges and ewight burning. So, while you Non-GMO Vitamin Supplement be cutting calories Team-building fitness challenges popping weigt weight loss supplements, could CoQ10 be Nut Snack Subscription best-kept weight-loss secret? This article dives into the details of CoQ10 and how it may support weight loss efforts. But the reason we need CoQ10 for optimal function is because of one specific organelle: mitochondria. Ubiquinone CoQ10 is one of two mobile carriers that move electrons between enzyme complexes during the energy production cycle in mitochondria 2. Without this step, the respiratory chain becomes dysfunctional, and energy production suffers, thereby reducing the efficiency of cells and interfering with energy levels 2. The bulk of energy is produced in mitochondria through oxidative phosphorylation. Metrics qeight. In previous study, we found Coenzyme Q and weight loss coenzyme Q10 CoQ10 improved Low-carb and heart health profile in dyslipidemic individuals, but the annd is not yet clear. Adipokines have been demonstrated to be vital targets of metabolic diseases. The hypothesis that adipokines mediate the association of CoQ10 on glucolipid metabolism needs to be further studied in human. In this randomized, double-blinded, placebo-controlled trial, dyslipidemic individuals were administrated to mg CoQ10 or placebo for 24 weeks.
0 thoughts on “Coenzyme Q and weight loss”